Tamoxifen as a potential antileishmanial agent: Efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 365-368

  Miguel, Danilo C ^a   Zauli Nascimento, Rogéria C ^a   Yokoyama Yasunaka, Jenicer K U ^a   Katz, Simone ^b   Barbiéri, Clara L ^b   Uliana, Silvia R B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemotherapy; Cutaneous leishmaniasis; Selective oestrogen receptor modulator; SERM; Visceral leishmaniasis

Indexed keywords

CREATININE; MEGLUMINE ANTIMONATE; TAMOXIFEN; UREA;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CELL ASSAY; CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMSTER; IC 50; IN VIVO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LIVER; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; SPLEEN; SURVIVAL RATE; UREA BLOOD LEVEL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; FEMALE; INHIBITORY CONCENTRATION 50; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; PARASITIC SENSITIVITY TESTS; SKIN; SPLEEN; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 58849145630     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn509     Document Type: Article

References (14)

1. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2: E313.
2. Murray WH, Berman JD, Davies CR et al. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
3. Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-13.
4. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 526-34.
5. Miguel DC, Yokoyama-Yasunaka JK, Uliana SR. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis 2008; 2: E249.
6. Gebre-Hiwot A, Tadesse G, Croft SL et al. An in vitro model for screening antileishmanial drugs: The human leukaemia monocyte cell line, THP-1. Acta Trop 1992; 51: 237-45.
7. de Moura TR, Novais FO, Oliveira F et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect Immun 2005; 73: 5827-34.
8. Pontiggia O, Rodriguez V, Fabris V et al. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: A new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat 2008, in press.
9. Beggs WH. Drug protonation and pH in relation to the lethal action of tamoxifen on Candida albicans. J Antimicrob Chemother 1996; 37 841-2.
10. DeGregorio MW, Wilbur BJ, Coronado E et al. Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol 1987; 20: 316-8.
11. Vergel C, Palacios R, Cadena H et al. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment. J Infect Dis 2006; 194: 503-11.
12. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-41.
13. Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 2007; 9: 561-70.
14. Yildiz A, Guleryuz S, Ankerst DP et al. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65: 255-63.